Monte Rosa Therapeutics (GLUE) Operating Income (2020 - 2026)

Monte Rosa Therapeutics' Operating Income history runs 7 years deep, the most recent figure standing at -$50.0 million for Q1 2026.

• On a quarterly basis, Operating Income fell 213.62% year-over-year to -$50.0 million in Q1 2026; TTM through Mar 2026 was -$148.3 million, a 6864.68% decrease from a year earlier, with the FY2025 full-year figure at -$54.2 million, up 33.17% from the prior year.
• Operating Income retreated to -$50.0 million in Q1 2026 per GLUE's latest filing, from -$49.7 million in the prior quarter.
• Across five years, Operating Income topped out at $44.0 million in Q1 2025 and bottomed at -$50.0 million in Q1 2026.
• The 5-year median for Operating Income is -$32.6 million (2024), against an average of -$25.9 million.
• Biggest YoY gain for Operating Income was 226.01% in 2025; the steepest drop was 482.31% in 2025.
• Year by year, Operating Income stood at -$32.5 million in 2022, then decreased by 7.31% to -$34.9 million in 2023, then surged by 137.3% to $13.0 million in 2024, then tumbled by 482.31% to -$49.7 million in 2025, then decreased by 0.64% to -$50.0 million in 2026.
• Per Business Quant, the three latest GLUE Operating Income figures stand at -$50.0 million (Q1 2026), -$49.7 million (Q4 2025), and -$33.0 million (Q3 2025).